S1P modulating agents

Patent metadata

Field	Value
Publication number	US-9765016-B2
Application number	US-201414763893-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Jan 29, 2013
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G( )y) dimers.

First claim

What is claimed is:

1. A compound represented by formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
X is O, S(O) r , NR 12 , C(O) or CH 2 ;
A 1 is CR 2 ;
A 2 is CR 3 ;
A 3 , A 4 , A 5 and A 6 are each independently CR 2 or C(R 2 ),
“- - - - - -” indicates a double or a single bond;
R 1 is a C 6-20 alkyl, a C 3-14 carbocyclyl, a 3- to 15-membered heterocyclyl, a C 6-10 aryl, or a five- to 14-membered heteroaryl, wherein the heterocyclyl and the heteroaryl comprise from 1 to 10 heteroatoms independently selected from N, S or O, and wherein R 1 may be optionally substituted with from one to six independently selected R 6 ;
R 2 and R 3 , for each occurrence, are independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, carboxy, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 3-8 halocycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 3-8 cycloalkoxy, C 3-8 halocycloalkoxy, C 1-6 alkanoyl, amino, N—(C 1-6 alkyl)amino, N,N-di-(C 1-6 alkyl)amino, C 1-6 alkoxycarbonyl, C 1-6 alkanoyloxy, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N-di-(C 1-6 alkyl)carbamoyl, C 1-6 alkylamido, mercapto, C 1-6 alkylthio, C 1-6 alkylsulfonyl, sulfamoyl, N—(C 1-6 alkyl)sulfamoyl, N,N-di-(C 1-6 alkyl)sulfamoyl, and C 1-6 alkylsulfonamido;
R 5 is a C 1-6 alkyl, C 3-8 carbocyclyl, a 3- to 8-membered heterocyclyl, C 6-10 aryl, a 5- to 10-membered heteroaryl, a bridged ring system comprising from 6 to 12 ring members, a spiro ring system comprising from 5-14 ring members; or a bicyclic ring system represented by the following formula:

wherein B′ and B″ are independently selected from the group consisting of monocyclic C 3-8 carbocyclyl, a monocyclic 3- to 8-membered heterocyclyl, phenyl or a 5- to 6- membered heteroaryl; wherein R 5 may be optionally substituted with from 1 to 4 independently selected R 7 ;
R 6 , for each occurrence, is independently selected from the group consisting of halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 6-10 aryl, C 1-6 alkoxy-C 1-6 alkyl, and tri-(C 1-6 alkyl)silyl; or two R 6 that are attached to the same carbon atom may form C 3-8 spirocycloalkyl or 3- to 8-membered spiroheterocycloalkyl;
R 7 , for each occurrence, is independently halo, hydroxyl, nitro, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-4 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 halocycloalkyl, C 3-8 cycloalkoxy, C 3-8 halocycloalkoxy, —NR a R b , —C(O)NR a R b , —N(R a )C(O)R b , —C(O)R a , —S(O) r R a , or —N(R a )S(O) 2 R b ;
R 8 and R 9 are each independently hydrogen, a carboxy, C 1-6 alkyl, or a C 2-6 alkenyl; or R 8 and R 9 together with the carbon to which they are attached are —C(═O)—, a C 3-8 spirocycloalkyl, or a 3- to 8-membered spiroheterocycloalkyl;
R 10 and R 12 are each, independently, hydrogen or a C 1-6 alkyl;
R 11 is —OH, —C(O)OR 15 , —C(O)N(R 16 ) 2 , —C(O)N(R 15 )—S(O) 2 R 15 , —S(O) 2 OR 15 , —C(O)NHC(O)R 15 , —Si(O)OH, —B(OH) 2 , —N(R 15 )S(O) 2 R 15 , —S(O) 2 N(R 15 ) 2 , —O—P(O)(OR 15 ) 2 , —P(O)(OR 15 ) 2 , —CN, —S(O) 2 NHC(O)R 15 , —C(O)NHS(O) 2 R 15 , —C(O)NHOH, —C(O)NHCN, or a heteroaryl or a heterocyclyl selected from the group consisting of formulae (a)-(i′):

R 15 for each occurrence is independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 6-10 aryl, a 5 to 14 membered heteroaryl, and a 3 to 15 membered heterocyclyl; wherein the heteroaryl or heterocyclyl comprises from 1 to 10 heteroatoms independently selected from O, N, or S; and wherein R 15 may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, C 1-4 alkoxy, C 1-4 alkyl, cyano, nitro, hydroxyl, amino, N—(C 1-4 alkyl)amino, N,N-di-(C 1-4 alkyl)amino, carbamoyl, N—(C 1-4 alkyl)carbamoyl, N,N-di-(C 1-4 alkyl)carbamoyl, C 1-4 alkylamido, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonamido, sulfamoyl, N—(C 1-4 alkyl)sulfamoyl, and N,N—(C 1-4 dialkyl)-sulfamoyl;
R 16 is R 15 ; or two R 16 together with the nitrogen atom to which they are attached form a 5 to 14 membered heteroaryl or a 3 to 15 membered heterocyclyl, wherein the heteroaryl or heterocyclyl comprises from 1 to 10 heteroatoms independently selected from O, N, or S; and wherein the heteroaryl or heterocyclyl may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, C 1-4 alkoxy, C 1-4 alkyl, cyano, nitro, hydroxyl, amino, N—(C 1-4 alkyl)amino, N,N-di-(C 1-4 alkyl)amino, carbamoyl, N—(C 1-4 alkyl)carbamoyl, N,N-di-(C 1-4 alkyl)carbamoyl, C 1-4 alkylamido, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonamido, sulfamoyl, N—C 1-4 alkylsulfamoyl, and N,N—(C 1-4 dialkyl)-sulfamoyl;
R 17 and R 18 , for each occurrence, are each independently hydrogen, a halo, or a C 1-4 haloalkyl;
R 19 for each occurrence is independently selected from the group consisting of hydrogen, carboxy, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 3-8 halocycloalkyl, C 1-6 alkanoyl, C 1-6 alkoxycarbonyl, carbamoyl, N—(C 1-6 alkyl)carbamoyl, N,N-di-(C 1-6 alkyl)carbamoyl, C 1-6 alkylsulfonyl, sulfamoyl, N—(C 1-6 alkyl)sulfamoyl, and N,N-di-(C 1-6 alkyl)sulfamoyl;
R a and R b , for each occurrence, are independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 6-10 aryl, or C 3-8 halocycloalkyl;
R c is hydrogen or a C 1-4 alkyl;
m is 0 or 1, provided that when m is 0, R 5 comprises at least one nitrogen;
n is an integer from 1 to 6;
p is 0 or an integer from 1 to 6, and
r, for each occurrence, is independently 0, 1, or 2, provided that the compound is not
methyl 2-(((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)amino)acetate;
2-(((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)amino)acetic acid;
4-(((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl) amino)butanoic acid;
methyl 1-((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)azetidine-3-carboxylate;
1-((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)azetidine-3-carboxylic acid;
ethyl 3-(((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)amino)propanoate;
3-(((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)amino)propanoic acid;
methyl 1-((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)pyrrolidine-3-carboxylate; or
1-((2-((4-(tert-butyl)cyclohexyl)oxy)-4-methylnaphthalen-1-yl)methyl)pyrrolidine-3-carboxylic acid.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is a halo, C 1-6 alkyl, C 1-6 haloalkyl or cyano.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is substituted by —(CR 17 R 18 ) p —R 7 and is optionally substituted by from 1 to 3 independently selected R 11 .

4. The compound of claim 1 ,

Assignees

• Biogen Ma Inc

Inventors

• Guckian Kevin
• Kumaravel Gnanasambandam
• Liu Xiaogao
• Ma Bin
• Peng Hairuo

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P5/48

  of the pancreatic hormones · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/02

  Antidotes · CPC title